AstraZeneca in $560 m deal for respiratory firm
British drugmaker AstraZeneca PLC says it is to acquire Pearl Therapeutics Inc., a Redwood-City, California-based company involved in therapies for asthma and chronic obstructive pulmonary disease for at least $560 million.
Jun 10, 2013
not rated yet |
0